Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anitocabtagene-autoleucel in relapsed/refractory multiple myeloma
NCT04155749Phase 1Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Dec 2019
- Primary completion
- Oct 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anitocabtagene autoleucel in multiple myeloma (MM), sponsored by Kite Pharma. Primary endpoints: Treatment-Emergent Adverse Events at 24 months and Recommended Phase 2 Dose at 24 months. Started Dec 2019; status: active, not recruiting.
02
Drugs
anitocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04155749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155749.